Iovance Biotherapeutics Reports Q4 Revenue Beat, FDA Fast Track for Lung Cancer

Iovance Biotherapeutics reported Q4 2025 revenue of approximately $87 million, exceeding the consensus estimate of $81.61 million, and posted a loss of $0.18 per share, beating analysts' consensus estimates of $0.22 by $0.04. The biotechnology company saw its stock rise to $4.17 from a previous close of $3.78 following the earnings announcement.

Sales of Amtagvi (lifileucel) reached $65 million in Q4 2025, up approximately 33% from $48.7 million a year ago. Total product revenue for the full year 2025 reached $264 million, aligning with the company's guidance range of $250-$300 million. The gross margin improved from 43% in Q3 to 50% in Q4, indicating progress in cost control and operational efficiency.

The company received FDA fast-track designation for lifileucel in second-line non-small cell lung cancer. Lifileucel has secured FDA approval for metastatic melanoma and reported favorable real-world response and safety data. Iovance plans expanded registrational trials for the therapy.

A pilot TIL trial reported a 50% objective response rate in advanced soft-tissue sarcomas (undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma). Forty-one evaluable patients with previously treated advanced melanoma received commercial Amtagvi as per the U.S. prescribing information at four authorized treatment centers. The physician-assessed confirmed objective response rate was 44% and the disease control rate was 73%, with the response rate being higher with earlier Amtagvi treatment.

Amtagvi is the first one-time T cell therapy for a solid tumor cancer and the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where applicable. The company is also marketing Proleukin (aldesleukin), an interleukin-2 product used in the Amtagvi treatment regimen.

As of December 31, 2025, Iovance reported a cash reserve of approximately $303 million in cash and short-term investments, expected to sustain operations into Q3 2027. The company had a negative net margin of 158.78% and a negative return on equity of 55.24%.

Analyst coverage shifted following the earnings report. Citizens JMP upgraded Iovance from Market Perform to Market Outperform and set a $5 price target. Chardan Capital lowered their price objective from $17.00 to $16.00 while maintaining a buy rating. Barclays increased their price target from $9.00 to $10.00 with an overweight rating. On February 5, one firm reaffirmed a sell rating and issued a $2.00 price target, up from $1.50. HC Wainwright reduced their price objective from $20.00 to $9.00 with a buy rating. Six research analysts have rated the stock with a buy rating, five have given a hold rating and two have given a sell rating, resulting in a consensus rating of "Hold" and a consensus price target of $9.91.